Sinofarm WIBP COVID-19 vaksinasi

Vikipediya, ochiq ensiklopediya

Sinofarm WIBP COVID-19 vaksinasi, shuningdek WIBP-CorV nomi bilan ham tanilgan[1][2]. Sinofarm tomonidan ishlab chiqilgan ikki faolsizlangan virusli COVID-19 vaksinalaridan biri. Tekshiruv natijalari shuni koʻrsatadiki,vaksina simptomatik holatlarga qarshi 72,8% va ogʻir holatlarga qarshi 100% ta taʼsir koʻrsatadi (emlangan guruhda 26 holat va platsebo guruhida 95 ta holatda)[3]. Sinofarm tomonidan ishlab chiqilgan boshqa virusli COVID-19 vaktsinasi — BIBP vaktsinasi (BBIBP-CorV) boʻlib, u nisbatan muvaffaqiyatliroqdir. Yiliga 1 milliard dona doza ishlab chiqariladi.

Tibbiyotda foydalanilishi[tahrir | manbasini tahrirlash]

Vaksina mushak orasiga inʼektsiya yoʻli orqali qilinadi. 3 haftada 2 dozadan buyuriladi[4][5][6].

Samaradorligi[tahrir | manbasini tahrirlash]

2021-yil may oyida Birlashgan Arab Amirliklari va Bahrayndagi III bosqichli sinovlarining JAMA-da ekspertlar tomonidan koʻrib chiqilgannatijalar vaksina simptomatik holatlarga qarshi 72,8% va ogʻir holatlarga qarshi 100% samarali ekanligini koʻrsatdi emlangan guruhda 26 ta holat va platseboda 95 holat). Ushbu sinovlarda 12 743 kishi vaksina va 12 737 kishi platsebo oldi[7].

Ishlab chiqarish[tahrir | manbasini tahrirlash]

2021-yil iyun oyida yiliga 1 milliard doza ishlab chiqaradigan yangi zavod oʻz ishini boshladi[8].

Tarixi[tahrir | manbasini tahrirlash]

2020-yil aprel oyida Xitoy Sinofarm Pekin Biologik Mahsulotlar Instituti (BIBP)[9] va Uxan Biologik Mahsulotlar Instituti (WIBP) tomonidan ishlab chiqilgan nomzod COVID-19 vaksinasining klinik sinovlarini tasdiqladi[10]. Ikkala vaksina ham COVID-19 uchun kimyoviy faolsizlantirilgan butun virusga qarshi vaksinalardir.

2020-yil 13-avgustda Uxan Biologik Mahsulotlari Instituti I bosqich (96 nafar kattalar) va II bosqich (224 nafar kattalar)) klinik tadqiqotlarning oʻrtacha natijalarini eʼlon qildi. Hisobotda keltirilishicha vaksina salbiy taʼsirlarning past darajasi va immunogenligini koʻrsatadi, ammo xavfsizlik va samaradorlikni uzoq muddatli baholash uchun III bosqichli sinovlarni talab etadi[11].

Klinik sinovlar[tahrir | manbasini tahrirlash]

2021-yil mart oyida Peruda BIBP va WIBP sinovlari oʻtkazuvchi Cayetano Heredia universiteti samaradorlikni pasaytirish uchun WIBP sinovlari tadqiqotlarda ishtirokchilarga kamroq samaradorlik koʻrsatgani uchun uni toʻxtatish va ishtirokchilarga uning oʻrniga BIBP vaksinasini taklif qilishini eʼlon qildi, va bunda samaradorligi yuqori boʻldi[12].

Ruxsatnomalar[tahrir | manbasini tahrirlash]

2021-yil 25-fevralda Xitoy vaksinasi umumiy foydalanish uchun tasdiqlandi[13].

New York Times gazetasining yozishicha, vaksina faqat Birlashgan Arab Amirliklarida cheklangan, vaksina foydalanish uchun tasdiqlanmagan[14]. 2021-yil 19-avgustda Filippin vaksinani favqulodda foydalanishga ruxsat berdi[15].

Manbalar[tahrir | manbasini tahrirlash]

  1. ↑ Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine (PDF). World Health Organization. „Evaluated BBIBP-CorV & WIBP-CorV“
  2. ↑ „Covid-19 vaccines and variants of concern: A review“. Reviews in Medical Virology. 32-jild, № 4. July 2022. e2313-bet. doi:10.1002/rmv.2313. PMC 8646685. PMID 34755408.
  3. ↑ „Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial“. JAMA. 326-jild, № 1. July 2021. 35–45-bet. doi:10.1001/jama.2021.8565. PMC 8156175. PMID 34037666.
  4. ↑ China National Biotec Group Company Limited (29 October 2020). „Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above“. G42 Healthcare company, Abu Dhabi Health Services Company, Wuhan Institute of Biological Products Co., Ltd, Beijing Institute of Biological Products Co Ltd. {{cite magazine}}: Cite magazine requires |magazine= (yordam)
  5. ↑ Universidad Peruana Cayetano Heredia (3 November 2020). „Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru (Covid-Peru)“. National University of San Marcos, Peru. NCT04612972. {{cite magazine}}: Cite magazine requires |magazine= (yordam)
  6. ↑ „Two Chinese-developed COVID-19 vaccines under review“. National Medical Products Administration (2021-yil 25-fevral). Qaraldi: 2021-yil 11-aprel.
  7. ↑ name="jama.2021.85652"> „Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial“. JAMA. 326-jild, № 1. July 2021. 35–45-bet. doi:10.1001/jama.2021.8565. PMC 8156175. PMID 34037666.Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, Hussein SE, Al Mazrouei SK, Al Karam M, Li X, Yang X, Wang W, Lai B, Chen W, Huang S, Wang Q, Yang T, Liu Y, Ma R, Hussain ZM, Khan T, Saifuddin Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I, Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X (July 2021). „Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial“. JAMA. 326 (1): 35-45. doi:10.1001/jama.2021.8565. PMC 8156175. PMID 34037666.
  8. ↑ „Sinopharm's Wuhan affiliate boosts COVID-19 shot annual capacity to 1 billion doses“ (en). CNA. 2021-yil 8-iyunda asl nusxadan arxivlangan. Qaraldi: 2021-yil 8-iyun.
  9. ↑ „Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial“. The Lancet. Infectious Diseases. 21-jild, № 1. January 2021. 39–51-bet. doi:10.1016/s1473-3099(20)30831-8. PMC 7561304. PMID 33069281.
  10. ↑ „Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials“. JAMA. 324-jild, № 10. September 2020. 951–960-bet. doi:10.1001/jama.2020.15543. PMC 7426884. PMID 32789505.
  11. ↑ name=":1">„Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials“. JAMA. 324-jild, № 10. September 2020. 951–960-bet. doi:10.1001/jama.2020.15543. PMC 7426884. PMID 32789505.Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X (September 2020). „Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials“. JAMA. 324 (10): 951-960. doi:10.1001/jama.2020.15543. PMC 7426884. PMID 32789505.
  12. ↑ „COMUNICADO A LA OPINIÓN PÚBLICA“. Universidad Peruana Cayetano Heredia (2021-yil 9-mart).
  13. ↑ „China approves two more domestic COVID-19 vaccines for public use“ (en). Reuters (2021-yil 25-fevral). Qaraldi: 2021-yil 30-mart.
  14. ↑ „Coronavirus Vaccine Tracker“ (en-US). The New York Times (2020-yil 10-iyun). Qaraldi: 2021-yil 30-mart.
  15. ↑ „FDA grants EUA to COVID-19 vaccine Sinopharm manufactured by Wuhan affiliate“. Manila Bulletin (2021-yil 25-avgust). 
"https://uz.wikipedia.org/w/index.php?title=Sinofarm_WIBP_COVID-19_vaksinasi&oldid=4308694" dan olindi